ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
Press release – No. 17 / 2025
REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025
Copenhagen, Denmark, December 1, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, is hosting a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity and metabolism.
Time: December 11, 2025, from 1.00-5.30pm GMT (2.00-6.30pm CET) Venue: Goldman Sachs International, Plumtree Court, 2 Stonecutter Street, London EC4A 4AU Register for in-person or virtual attendance: Registration | Zealand Pharma Capital Markets Day
A replay of the webcast will be archived on the company’s website following the presentation.
Zealand Pharma speakers:
Adam Steensberg, Chief Executive Officer
Henriette Wennicke, Chief Financial Officer
David Kendall, Chief Medical Officer
Eric Cox, Chief Commercial Officer
Utpal Singh, Chief Scientific Officer
External experts:
Dr. Carel Le Roux, MBChB, MSC, FRCP, FRCPath, PhD, Professor of Experimental Pathology at University College Dublin
Jonathan Roth, PhD, Metabolic researcher and pioneer in amylin-leptin biology
Louis J. Aronne, MD, FACP, DABOM, Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College
About Zealand Pharma Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit www.zealandpharma.com.
Contacts Adam Lange (Investors) Vice President, Investor Relations Zealand Pharma Email: alange@zealandpharma.com
